COPENHAGEN (Reuters) – Novo Nordisk will explore how GLP-1 drugs potentially could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.
(Reporting by Louise Breusch Rasmussen, editing by Stine Jacobsen)
Comments